Welcome to our dedicated page for Sana Biotechnology news (Ticker: SANA), a resource for investors and traders seeking the latest updates and insights on Sana Biotechnology stock.
Sana Biotechnology, Inc. (NASDAQ: SANA) is a biotechnology company focused on creating and delivering engineered cells as medicines, and its news flow reflects this emphasis on cell and gene-based therapies. Company press releases and updates describe progress across its hypoimmune platform for allogeneic cell therapies and its fusogen platform for in vivo delivery of genetic payloads.
Investors following SANA news can read about clinical and preclinical milestones in type 1 diabetes, B-cell cancers, and B-cell–mediated autoimmune diseases. Sana has reported investigator-sponsored clinical data for UP421, a primary human pancreatic islet cell therapy engineered with hypoimmune technology, including results showing survival and function of transplanted beta cells without immunosuppression. News items also cover development of SC451, an O-negative, HIP-modified, iPSC-derived pancreatic islet cell therapy, and in vivo CAR T candidates such as SG299 and SG293 built on the fusogen platform.
In addition to scientific and clinical updates, Sana’s news includes quarterly financial results, portfolio prioritization decisions, and capital-raising activities through public offerings and at-the-market equity programs. The company also issues announcements about participation in healthcare and investor conferences, where management provides business overviews and program updates.
This news page aggregates these disclosures so readers can monitor developments in Sana’s engineered cell programs, regulatory interactions, scientific publications, and financing events associated with the SANA stock. For investors and observers of the biotechnology sector, the SANA news stream offers insight into how the company is advancing its platforms and concentrating resources on type 1 diabetes and in vivo CAR T approaches.
Sana Biotechnology, Inc. (NASDAQ: SANA) will present at the Guggenheim Healthcare Talks 5th Annual Oncology Conference on February 9, 2023, at 1:00 p.m. ET. The presentation, led by CEO Steve Harr, will offer a business overview and update. Interested parties can access the live webcast on Sana's Investor Relations page and view a replay for 30 days post-conference. Founded to create engineered cell therapies, Sana aims to revolutionize disease treatment. The company operates in Seattle, Cambridge, South San Francisco, and Rochester.
Sana Biotechnology (NASDAQ: SANA) announced FDA clearance for its SC291 Investigational New Drug (IND) application, allowing a first-in-human study focusing on B-cell malignancies. SC291, a CD19-targeted allogeneic CAR T cell therapy, utilizes Sana's hypoimmune platform designed to evade immune rejection, potentially increasing treatment efficacy. The company aims to report initial clinical data later this year and is also working on a second IND for SC262, targeting CD22. CEO Steve Harr emphasized the importance of SC291 in providing new options for difficult cancers and highlighted the platform's broader applications, including treatments for type 1 diabetes.
Sana Biotechnology (NASDAQ: SANA) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 3:45 p.m. PT. CEO Steve Harr will provide a business overview during the webcast, accessible via Sana's Investor Relations page. A replay will be available for 30 days. Sana focuses on engineered cell therapies aimed at repairing and controlling genes and replacing damaged cells. The company operates in Seattle, Cambridge, South San Francisco, and Rochester.
Sana Biotechnology (NASDAQ: SANA) presented data at the 64th American Society of Hematology Annual Meeting, showcasing advancements in its hypoimmune CAR T cell programs. The HIP platform, designed to evade immune detection, demonstrated efficacy in eradicating CD19+ tumors in preclinical models. Key highlights included the scalable production of CAR T cells using CRISPR/Cas12b and promising results for dual-targeted therapies against BCMA and CD19. Sana plans to file three IND applications in the coming years, starting with SC291 targeting CD19-positive cancers in 2023.
Sana Biotechnology (NASDAQ: SANA) has announced a strategic portfolio prioritization aimed at optimizing clinical development and maintaining a strong cash runway into 2025. The company anticipates filing Investigational New Drug (IND) applications for SC291, SG295, and SC263 in 2023, while SC451 and a BCMA-targeted CAR T candidate are scheduled for 2024. However, internal investment in the SC187 program will be discontinued, resulting in a 15% workforce reduction. The firm remains committed to advancing its key clinical programs and improving its engineered cell therapies for serious diseases.
Summary not available.
Sana Biotechnology (NASDAQ: SANA) announced that it will present six abstracts, including two oral presentations, at the upcoming 64th American Society of Hematology Annual Meeting from December 10-13, 2022, in New Orleans, LA. The presentations will highlight the potential of Sana's allogeneic CAR T cell and in vivo delivery platforms for treating hematologic malignancies. Key topics include CD19, CD22, and BCMA-targeted therapeutics. The company aims to advance therapies for lymphoma, leukemia, and multiple myeloma, with a focus on innovative approaches to enhance therapeutic efficacy.
Sana Biotechnology, Inc. (NASDAQ: SANA) reported Q3 2022 results, highlighting a cash position of $511.6 million. The company expects to file IND applications for SC291 and SC276 in 2023, with clinical data following. Research and development expenses rose significantly to $76.7 million due to increased headcount and third-party manufacturing costs. Net loss for the quarter was $85.1 million, slightly worse than in 2021. Despite these losses, Sana maintains a robust cash runway into 2025, supporting ongoing development of its innovative CAR T therapies and hypoimmune platform.
Cellarity, a life sciences company, announced the successful completion of a $121 million Series C financing, raising total funds to $274 million. This round attracted new investors, including Kyowa Kirin Co. Ltd and Hanwha Impact Partners, alongside existing backers. The funds will be used to expand talent, enhance its platform, and progress its drug pipeline. Cellarity’s innovative approach focuses on cellular dysfunction rather than targeting individual molecules, aiming for breakthroughs in treating various diseases.
Sana Biotechnology, Inc. (NASDAQ: SANA) announced webcasts for its presentations at two upcoming investor conferences. Steve Harr, the President and CEO, will provide a business overview on September 13 and September 29, 2022, at the Morgan Stanley 20th Annual Global Healthcare Conference and the Jefferies Cell and Genetic Medicine Summit, respectively. The presentations will be available on the Investor Relations page of Sana's website, with replays accessible for 30 days after each event.